ArticleTransfusion2025
Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.Annals of hematology · 2026Review
- Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEvidence guiding optimal transfusion practice for patients with myelodysplastic syndromes (MDS) is lacking. Many patients have concurrent cardiac disease. Data on practice are sparse. We aimed to describe the use of red blood cell (RBC) transfusion and the prevalence of cardiac comorbidities in patients with MDS within Australia's largest public hospital network to better understand real-world practices and outcomes.
methodsWe conducted a retrospective cohort study of patients aged ≥18 years with MDS, MDS/myeloproliferative overlap neoplasm or chronic myelomonocytic leukemia admitted from 2016 to 2018 to determine RBC transfusion-related endpoints.
resultsOne hundred and seventy-nine patients (median age 78 years, 61.5% male) were included, with a median follow-up of 46 weeks. Of these, 102 (57.0%) received RBC transfusion. Transfused patients had lower presenting Hb (87 vs. 105 g/L, p < 0.0001), higher rates of cardiac disease (29.4% vs. 12.9%, p = 0.009) and 5-azacytidine use (31.4% vs. 13.0%, p = 0.004). Sixty-five patients (36.3%) received outpatient RBC transfusions, with a median of 2 units RBC per transfusion and 14 days between transfusions. The median pre-transfusion Hb was 80 g/L (IQR 74-86 g/L). Forty patients (22.4%) had evidence of cardiac disease, with similar pre-transfusion Hb for patients with and without cardiac disease (median Hb 79 g/L vs. 81 g/L, p = 0.1). DISCUSSION: Patients with MDS frequently require RBC transfusion, and restrictive transfusion strategies predominate despite many patients having cardiac comorbidities. Further research is needed to address optimal transfusion strategies in such patients and associated cardiac outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.